Mironid

Executive Summary

Mironid is a UK-based biotechnology company founded in 2015, focused on developing novel small-molecule therapeutics for rare kidney diseases, with a primary target of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's approach involves modulating cAMP-degrading phosphodiesterase (PDE) enzymes to directly target the central signaling mechanism driving ADPKD. Despite being in early stages, Mironid's focused strategy on a well-validated biological pathway offers potential for disease modification in a condition with high unmet need. The company is privately held and has not disclosed significant funding or pipeline details, but its scientific rationale and orphan drug potential position it for future growth. Key upcoming catalysts include advancement of its lead candidate into clinical trials, potential partnership or licensing deals, and funding rounds to support development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead PDE Modulator40% success
• Q3 2026Series A or B Funding Round50% success
• Q2 2026Preclinical Data Publication or Presentation at Major Conference70% success